Publications

Peer-reviewed cancer prevention and translational research, plus selected conference abstracts.

Focus areas: Lynch syndrome chemo- and immunoprevention, anti-Fusobacterium nucleatum vaccine development, colorectal cancer biomarkers.

Peer-reviewed articles

• Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology (2021).
• Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum. Journal of Proteomics (2019).
• Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut (2021).
• ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer. Oncotarget (2019).
• Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome. Journal of the National Cancer Institute (2024).

Selected conference abstracts

• Abstract 2732: Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer. Cancer Research (2019).
• Abstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Cancer Research (2020).
• Abstract 717: Mouse model for the development of preventive and therapeutic vaccines against microsatellite-unstable cancers. Cancer Research (2018).